What Wall Street Doesn’t Want You to Know About Hospital Emergency Rooms
A coronavirus whistleblower winds up also exposing that private equity has too much say in running emergency rooms.
Read more...A coronavirus whistleblower winds up also exposing that private equity has too much say in running emergency rooms.
Read more...Key public officials are abusing their position if they keep the severity of their Covid-19 illness under wraps.
Read more...The US is well into the Covid-19 crisis, yet most citizens are at risk of big bills if they seek testing and care.
Read more...The US may be about to be exceptional…in not a good way.
Read more...This should be a time for a genuinely new approach, one fit for a world of rising disruption and disaster, one that would define a new, more democratic, less bellicose America.
Read more...Michael Hudson rings the changes on some of his favorite themes: the logic of ancient debt jubilees. and the role of finance in contemporary rent extraction.
Read more...Does Modern Monetary Theory take tax justice for granted?
Read more...Who gets a check? How much will the check be? How long will the check take to arrive? When will the checks stop?
Read more...Why you should hate the coronavirus “stimulus” bill.
Read more...Why preserving (big) corporate profits will not bail out the economy.
Read more...Is the Democratic Party redeemable?
Read more...As the world struggles with the pandemic, Boeing should be seen as the vector for a parallel epidemic. It’s Patient Zero in an epidemic of corporate failure. As we change the way we live our lives, corporations like Boeing should change the way they are run. Corporate mismanagement made this crisis worse and, if it doesn’t change, will make the recovery more difficult.
Read more...Another sign that America has gone banana republic: Brady Bonds, used in the Latin American debt crisis, would be suitable medicine for our corporate debt hangover.
Read more...The U.S. shale oil industry had considerable problems before Saudi Arabia and Russia launched their oil price war. What comes next?
Read more...Granting “orphan” drug status to Gilead Sciences for remdesivir, its potential coronavirus treatment, is a massive boon to the company.
Read more...